function getval(val){
 var a1=val.replace(/<\/?.+?>/g,"");
 var a2=a1.replace(/ /g,"");
 return a2;
}
//document.write('http://wxzl.cogonline.com/html/CeShiZhuanLanYi/WenZhang/YiShiBaoDao/813.html');
wx.config({
debug:  false, 
appId: 'wx85d01b1d7184c45d',
timestamp: 1714943742,
nonceStr: 'YEWn0uUOZYM0m0uh',
signature: '72e6af93e27e33a93d5160b8b132e2ab487bb506',
jsApiList: [ 
   'checkJsApi', 
   'onMenuShareTimeline', 
   'onMenuShareAppMessage', 
   'onMenuShareQQ', 
   'onMenuShareWeibo'
]
});
wx.ready(function () { 
	wx.onMenuShareTimeline({  
	title: '卵巢癌PARP抑制剂临床应用指南(2022版)', 
	link: 'http://wxzl.cogonline.com/html/CeShiZhuanLanYi/WenZhang/YiShiBaoDao/813.html',
	imgUrl: 'http://wxzl.cogonline.com/wp/logo.jpg',
	success: function () {
		//alert('fx-ok');
	},
	cancel: function () {
		//alert('fx-no');
	}
	});
	wx.onMenuShareAppMessage({  
		title: '卵巢癌PARP抑制剂临床应用指南(2022版)', 
		link: 'http://wxzl.cogonline.com/html/CeShiZhuanLanYi/WenZhang/YiShiBaoDao/813.html',
		imgUrl: 'http://wxzl.cogonline.com/wp/logo.jpg',
		desc: getval('卵巢癌是病死率最高的妇科恶性肿瘤，70%的卵巢癌患者就诊时已届临床晚期。新诊断卵巢癌初始治疗模式为肿瘤细胞减灭术和以铂类药物为基础的联合化疗。虽然大多数患者经过初始治疗可获得临床缓解，但仍有70%的患者在2～3年内复发，5年生存率一直徘徊在40%左右。近年来，多腺苷二磷酸核糖聚合酶（poly ADP ribose polymerase，PARP）抑制剂的问世为卵巢癌的治疗带来了重大变革，系列高级别循证医学证据表明在初始治疗或铂敏感复发治疗获得完全缓解（complete response，CR）和'),
		success: function () {
			//alert('fx-ok');
		},
		cancel: function () {
			//alert('fx-no');
		}
	});
});	
wx.error(function (res) {
	//alert(location.href.split('#')[0]);
	//alert('err:'+res.errMsg);  
});
if(location.href.indexOf("?") >= 1 ){
	location.href=location.href.substring(0,location.href.indexOf("?"));
}